COMPANY OVERVIEW

Samumed’s small-molecule drug platform is harnessing the innate restorative power of the Wnt pathway to reverse the course of severe and prevalent diseases.

---

LOCATION

San Diego, CA, USA

---

THERAPEUTIC AREAS

Autoimmune Disease

Fibrotic DIsease

Neurological DIsorders

Oncology

Respiratory Disease

---

WEBSITE

https://www.samumed.com/default.aspx

---

CAREER WEBSITE

https://www.samumed.com/careers/default.aspx

---

SOCIAL MEDIA

---

INVESTORS

---

---

PRESS RELEASES

Dec 1, 2020

Darrin M. Beaupre, M.D., Ph.D. joins Samumed as Chief Medical Officer, Oncology

Jun 1, 2020

Michael White, Ph.D. joins Samumed as Chief Scientific Officer

May 22, 2020

Samumed Announces Publication of Phase 2 Data on Lorecivivint, Now in Pivotal Trials for Knee Osteoarthritis

Nov 13, 2019

Samumed Presents Safety Data Analysis of Lorecivivint for Knee Osteoarthritis at the 2019 ACR Annual Meeting

Oct 2, 2019

Samumed Publishes Unique Mechanism of Action for SM08502 in Targeting Gastrointestinal Tumors

For More Press Releases

---